We are live on
!
Find out more
RhumbLine Advisers Portfolio holdings
AUM
$117B
1-Year Est. Return
29.66%
This Fund
S&P 500
This Quarter
Est. Return
+0.65%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.92%
AUM
$73.9B
AUM Growth
-$2.32B
(-3%)
Cap. Flow
-$2.03B
Cap. Flow
% of AUM
-2.75%
Top 10 Holdings %
Top 10 Hldgs %
22.54%
Holding
3,088
New
92
Increased
1,359
Reduced
1,564
Closed
46
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$60.7M |
| 2 |
Analog Devices
ADI
|
+$46.1M |
| 3 |
Alphabet (Google) Class A
GOOGL
|
+$37.3M |
| 4 |
Match Group
MTCH
|
+$28.2M |
| 5 |
GXO Logistics
GXO
|
+$19.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$89.3M |
| 2 |
iShares Core S&P 500 ETF
IVV
|
+$78.9M |
| 3 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$77.4M |
| 4 |
Apple
AAPL
|
+$77M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$70.1M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.91% |
| 2 | Financials | 14.2% |
| 3 | Healthcare | 13.07% |
| 4 | Consumer Discretionary | 12.09% |
| 5 | Communication Services | 9.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1976
Ameresco
AMRC
$1.36B
| $1.77M | ﹤0.01% |
30,278
+1,046
| +4% | +$68.9K |
|
1977
Collegium Pharmaceutical
COLL
$956M
| $1.77M | ﹤0.01% |
89,556
-11,495
| -11% | -$249K |
|
1978
TriCo Bancshares
TCBK
$1.83B
| $1.76M | ﹤0.01% |
40,572
+1,350
| +3% | +$54.7K |
|
1979
Core Laboratories
CLB
$521M
| $1.76M | ﹤0.01% |
63,326
-18,265
| -22% | -$556K |
|
1980
WisdomTree
WT
$3.22B
| $1.75M | ﹤0.01% |
309,245
-48,249
| -13% | -$296K |
|
1981
The RMR Group
RMR
$332M
| $1.75M | ﹤0.01% |
52,343
+10,685
| +26% | +$407K |
|
1982
Dillards
DDS
$9.56B
| $1.74M | ﹤0.01% |
10,104
-133
| -1% | -$25.3K |
|
1983
Seer Inc
SEER
$120M
| $1.74M | ﹤0.01% |
50,473
+33,990
| +206% | +$1.17M |
|
1984
iShares S&P 500 Value ETF
IVE
$49.8B
| $1.74M | ﹤0.01% |
11,958
| – | – |
|
|
SCS
1985
DELISTED
Steelcase
SCS
| $1.73M | ﹤0.01% |
136,499
+3,741
| +3% | +$51.6K |
|
1986
DXP Enterprises
DXPE
$2.98B
| $1.73M | ﹤0.01% |
58,393
-6,421
| -10% | -$197K |
|
1987
RE/MAX Holdings
RMAX
$242M
| $1.73M | ﹤0.01% |
55,400
-6,781
| -11% | -$225K |
|
1988
Coinbase
COIN
$40.5B
| $1.73M | ﹤0.01% |
7,585
+2,986
| +65% | +$735K |
|
1989
Helix Energy Solutions
HLX
$1.41B
| $1.72M | ﹤0.01% |
443,372
-55,140
| -11% | -$227K |
|
1990
Kura Oncology
KURA
$850M
| $1.72M | ﹤0.01% |
91,740
+2,900
| +3% | +$54.6K |
|
1991
NovaGold Resources
NG
$3.33B
| $1.72M | ﹤0.01% |
249,696
+7,136
| +3% | +$52.8K |
|
|
ENDP
1992
DELISTED
Endo International plc
ENDP
| $1.71M | ﹤0.01% |
527,084
-83,029
| -14% | -$293K |
|
1993
C4 Therapeutics
CCCC
$412M
| $1.71M | ﹤0.01% |
38,195
+3,630
| +11% | +$155K |
|
1994
Hawkins
HWKN
$2.71B
| $1.7M | ﹤0.01% |
48,712
-7,411
| -13% | -$256K |
|
1995
Reynolds Consumer Products
REYN
$5.59B
| $1.69M | ﹤0.01% |
61,662
+11,300
| +22% | +$323K |
|
1996
National Presto Industries
NPK
$989M
| $1.68M | ﹤0.01% |
20,423
+955
| +5% | +$85.6K |
|
1997
Schneider National
SNDR
$6.25B
| $1.67M | ﹤0.01% |
73,394
+22,397
| +44% | +$495K |
|
|
WSR
1998
DELISTED
Whitestone REIT
WSR
| $1.66M | ﹤0.01% |
170,012
-11,665
| -6% | -$107K |
|
1999
Bally's
BALY
$658M
| $1.66M | ﹤0.01% |
33,112
+1,407
| +4% | +$68.6K |
|
2000
Kosmos Energy
KOS
$1.48B
| $1.66M | ﹤0.01% |
560,154
+148,023
| +36% | +$361K |
|
Similar funds
VAM
RhumbLine Advisers's Q3 2021 Portfolio in Review
As of Q3 2021, RhumbLine Advisers held 3,088 positions worth $73.9B, down 3% from $76.2B the previous quarter. Its ten largest holdings account for 23% of the portfolio.
Trading was light in Q3 2021: portfolio turnover was 4.5%. RhumbLine Advisers opened 92 new positions and exited 46, leaving the 3,088-position portfolio largely intact.
By sector, the portfolio is most concentrated in Technology at 24% of assets, up from 23% a quarter earlier, followed by Financials and Healthcare.
- RhumbLine Advisers's largest Q3 2021 buy was GXO Logistics: 250,722 shares worth $19.7M.
- RhumbLine Advisers added most to Moderna in Q3 2021, an estimated $60.7M increase.
- RhumbLine Advisers's biggest Q3 2021 reduction was Microsoft, cutting an estimated $89.3M.
- RhumbLine Advisers fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $77.4M.
- RhumbLine Advisers's ten largest holdings make up 23% of its $73.9B portfolio in Q3 2021.
- RhumbLine Advisers opened 92 new positions and closed 46 in Q3 2021.
- RhumbLine Advisers's portfolio value fell 3% quarter-over-quarter to $73.9B.
Based on RhumbLine Advisers's 13F filing for Q3 2021, filed 12 Nov 2021.